How long after giving birth should a woman with a high HBV load stop taking tenofovir to prevent the spread of the virus to her unborn child?

Abstract

The goal of this research is to determine how long it takes for pregnant women with high hepatitis B virus (HBV)
loads to stop taking tenofovir disoproxil fumarate (TDF) after giving birth in order to prevent the infection from
reaching their unborn children. A total of seventy-seven pregnant women with high HBV densities who were seen
at the Southern Central Hospital in Yunan Province between February 2020 and February 2021 had their clinical
data retrospectively analyzed. They were divided into three groups according to when they stopped taking their
drugs: group A (24 participants), group B (26 participants), and group C (27 participants)—all based on the time
following delivery. Prior to birth, all three groups were administered TDF. The Roche detection system was used
to evaluate liver function using alanine aminotransferase (ALT). The fluorescent quantitative approach was used
to assess hepatitis B virus deoxyribonucleic acid (HBV-DNA). We used a chemiluminescence microparticle
immunoassay (CMIA) to assess hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg).
After2,4,8,12,18, and 24 weeks of drug abstinence, all tests were conducted. After2,4,8,12,18, and 24 weeks of
medication discontinuation, all metrics in all three patient groups reverted to normal values. One month after
delivery, 83 newborns tested negative for hepatitis B surface antigen and DNA, indicating a complete cessation of
transmission from mothers to their infants and the absence of HBV infection. There was no statistically significant
difference between groups A, B, and C in terms of the occurrence of adverse responses in pregnant women; the
rates were 16.67%, 19.24%, and 18.52%, respectively (p > 0.05). Researchers found no correlation between the
amount of time it took to wean the mother off of her medicine after giving birth and the therapeutic efficacy of
TDF for these women. In order to confirm the findings, future studies will need to use larger samples. Late
pregnancy and high levels of hepatitis B virus (HBV) are important concepts. The drug known as tenofovir
disoproxil fumarate, Prevention of human papillomavirus (HBV) transmission from mothers to their children,
Length of withdrawal.